Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 344 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Solid Neoplasm, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
Other · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Central Nervous System Neoplasm, Localized Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions
131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Grand Rapids, Michigan + 1 more
Conditions
Brain Tumors
Interventions
temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
16
States / cities
Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more
Conditions
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligodendroglioma
Interventions
lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, positron emission tomography, magnetic resonance imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
ziv-aflibercept, pharmacological study, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more
Conditions
Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant, Brain Tumor, Primary, Brain Tumor, Recurrent, Brain Tumors, Intracranial Neoplasms, Neoplasms, Brain, Neoplasms, Intracranial, Primary Brain Neoplasms, Primary Malignant Brain Neoplasms, Primary Malignant Brain Tumors, Gliomas, Glioblastoma
Interventions
5-ALA (Gliolan)
Drug
Lead sponsor
Constantinos Hadjipanayis
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Conditions
Brain and Central Nervous System Tumors
Interventions
cintredekin besudotox, isolated perfusion, conventional surgery
Biological · Drug · Procedure
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Conditions
Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)
Interventions
Sitagliptin, Bevacizumab
Drug · Biological
Lead sponsor
Kailin Yang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor
Interventions
erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 5 more
Conditions
Childhood Brain Neoplasm, Recurrent Childhood Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol Non-Stoichiometric Magnetite, Gadolinium
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
5 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California
Completed Phase 1 Interventional Results available

HUMC 1612: Optune NovoTTF-200A System

NCT03128047
Conditions
High Grade Glioma, Ependymoma
Interventions
Optune NovoTTF-200A System
Device
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
5 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Orlando, Florida • Hackensack, New Jersey
Conditions
Brain and Central Nervous System Tumors
Interventions
porfimer sodium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Brain and Central Nervous System Tumors, Sarcoma
Interventions
vatalanib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chicago, Illinois • Seattle, Washington
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
Interventions
Cabozantinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Trebananib
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
243
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 172 more
Conditions
Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
Interventions
Nivolumab, EKG, MRI Brain and/or spine, Body CT Scan, MDASI-BT, MDASI-SP
Drug · Diagnostic Test · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Houston, Texas
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Conditions
Glioma
Interventions
Enzastaurin (LY317615) monohydronchloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
erlotinib hydrochloride, temozolomide, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Arcadia, California
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, topotecan hydrochloride
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
2
States / cities
Durham, North Carolina • Memphis, Tennessee
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
carmustine in ethanol, conventional surgery
Drug · Procedure
Lead sponsor
Direct Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Conditions
Brain Tumor, Recurrent Brain Tumor, Brain Neoplasm, Recurrent Brain Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida